FR13C0037I2 - Solvat acetonique du dimethoxy docetaxel et son procede de preparation - Google Patents

Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Info

Publication number: FR13C0037I2
Authority: FR; France
Prior art keywords: preparation process; dimethoxy docetaxel; acetonic; solvate; acetonic solvate
Prior art date: 2003-09-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR13C0037C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharma SA

Original Assignee

Aventis Pharma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-19

Filing date

2013-07-04

Publication date

2015-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0037(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-04 Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA

2013-09-08 Publication of FR13C0037I1 publication Critical patent/FR13C0037I1/fr

2015-11-20 Application granted granted Critical

2015-11-20 Publication of FR13C0037I2 publication Critical patent/FR13C0037I2/fr

Status Active legal-status Critical Current

Links

ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
229960003668 docetaxel Drugs 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
239000012453 solvate Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Hematology (AREA)
Epoxy Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cephalosporin Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FR13C0037C 2003-09-19 2013-07-04 Solvat acetonique du dimethoxy docetaxel et son procede de preparation Active FR13C0037I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0311016A FR2859996B1 (fr)	2003-09-19	2003-09-19	Solvat acetonique du dimethoxy docetaxel et son procede de preparation
PCT/FR2004/002344 WO2005028462A1 (fr)	2003-09-19	2004-09-16	Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (2)

Publication Number	Publication Date
FR13C0037I1 FR13C0037I1 (fr)	2013-09-08
FR13C0037I2 true FR13C0037I2 (fr)	2015-11-20

Family

ID=34224354

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR0311016A Expired - Lifetime FR2859996B1 (fr)	2003-09-19	2003-09-19	Solvat acetonique du dimethoxy docetaxel et son procede de preparation
FR13C0037C Active FR13C0037I2 (fr)	2003-09-19	2013-07-04	Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FR0311016A Expired - Lifetime FR2859996B1 (fr)	2003-09-19	2003-09-19	Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Country Status (37)

Country	Link
US (1)	US7241907B2 (fr)
EP (1)	EP1667986B1 (fr)
JP (1)	JP5010279B2 (fr)
KR (1)	KR101123588B1 (fr)
CN (1)	CN100429207C (fr)
AR (1)	AR045667A1 (fr)
AU (1)	AU2004274212B2 (fr)
BE (1)	BE2013C036I2 (fr)
BR (1)	BRPI0414492A8 (fr)
CA (1)	CA2539309A1 (fr)
CR (1)	CR8292A (fr)
CY (2)	CY1114575T1 (fr)
DK (1)	DK1667986T3 (fr)
ES (1)	ES2403149T4 (fr)
FR (2)	FR2859996B1 (fr)
HR (1)	HRP20130322T1 (fr)
HU (1)	HUS1300025I1 (fr)
IL (1)	IL174240A (fr)
LU (1)	LU92172I2 (fr)
MA (1)	MA28045A1 (fr)
ME (2)	ME00054B (fr)
MX (1)	MXPA06002639A (fr)
MY (1)	MY136668A (fr)
NO (2)	NO335997B1 (fr)
NZ (1)	NZ545835A (fr)
PA (1)	PA8612401A1 (fr)
PE (1)	PE20050870A1 (fr)
PL (1)	PL1667986T3 (fr)
PT (1)	PT1667986E (fr)
RS (2)	RS20060189A (fr)
RU (1)	RU2342373C2 (fr)
SI (1)	SI1667986T1 (fr)
TN (1)	TNSN06086A1 (fr)
TW (1)	TWI382022B (fr)
UA (1)	UA87115C2 (fr)
WO (1)	WO2005028462A1 (fr)
ZA (1)	ZA200602255B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2001874A4 (fr) *	2006-03-21	2010-04-07	Reddys Lab Ltd Dr	Polymorphes de docétaxel et procédés
US7855591B2 (en) *	2006-06-07	2010-12-21	Atmel Corporation	Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) *	2006-09-05	2010-01-26	Atmel Corporation	High efficiency low cost bi-directional charge pump circuit for very low voltage applications
JP2010516625A (ja)	2007-01-24	2010-05-20	インサートセラピューティクス，インコーポレイテッド	制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
AU2013205442B2 (en) *	2008-01-17	2016-05-12	Aventis Pharma S.A.	Crystalline forms of dimethoxy docetaxel and methods for preparing same
FR2926551A1 (fr)	2008-01-17	2009-07-24	Aventis Pharma Sa	Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
KR101671537B1 (ko)	2008-08-11	2016-11-01	넥타르 테라퓨틱스	다분지형 중합체 알카노에이트 컨쥬게이트
FR2945211A1 (fr) *	2009-05-06	2010-11-12	Sanofi Aventis	Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
EA024186B1 (ru)	2009-10-29	2016-08-31	Авентис Фарма С.А.	Применение кабазитаксела в комбинации с преднизоном или преднизолоном для лечения рака простаты
AU2015200149B2 (en) *	2009-10-29	2016-12-01	Aventis Pharma S.A.	Novel antitumoral use of cabazitaxel
CA2708489A1 (fr) *	2009-10-29	2011-04-29	Aventis Pharma S.A.	Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate
WO2012088445A1 (fr)	2010-12-22	2012-06-28	Nektar Therapeutics	Conjugués promédicaments polymères à plusieurs bras de composés à base de cabazitaxel
WO2012088422A1 (fr)	2010-12-22	2012-06-28	Nektar Therapeutics	Conjugués promédicaments polymères à plusieurs bras de composés à base de taxane
WO2012142117A1 (fr)	2011-04-12	2012-10-18	Plus Chemicals Sa	Formes solides de cabazitaxel et procédés de préparation associés
WO2013024495A1 (fr) *	2011-08-18	2013-02-21	Dr. Reddys Laboratories Limited	Formulations pharmaceutiques de cabazitaxel
TWI526437B (zh) *	2011-09-09	2016-03-21	台灣神隆股份有限公司	卡巴他賽之結晶型
US8722900B2 (en)	2011-10-31	2014-05-13	Scinopharm Taiwan, Ltd.	Process for cabazitaxel, and intermediates thereof
DE112012004569T5 (de)	2011-11-01	2014-08-14	Fresenius Kabi Oncology Ltd.	Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon
ES2716799T3 (es)	2011-11-28	2019-06-17	Fresenius Kabi Oncology Ltd	Forma cristalina de cabazitaxel y proceso para la preparación de la misma
EP2791122B1 (fr)	2011-12-13	2019-01-23	Aventis Pharma S.A.	Forme cristalline du cabazitaxel et son procédé de préparation
US9403785B2 (en)	2012-01-03	2016-08-02	Shilpa Medicare Limited	Process for preparing amorphous cabazitaxel
SG11201404712UA (en) *	2012-02-10	2014-09-26	Aventis Pharma Sa	New pediatric uses of cabazitaxel
CN104220431A (zh)	2012-03-08	2014-12-17	伊瓦克斯国际有限责任公司	卡巴他赛的固态形式及其制备方法
CN102675257B (zh) *	2012-05-10	2014-07-02	上海金和生物技术有限公司	一种卡巴他赛晶体及其制备方法
CN102746258B (zh) *	2012-07-25	2015-02-04	重庆泰濠制药有限公司	卡巴他赛的结晶形式及其制备方法
US9012665B2 (en)	2012-07-31	2015-04-21	Yung Shin Pharm. Ind. Co., Ltd.	Amorphous cabazitaxel
EP2884963B1 (fr)	2012-08-15	2017-12-27	Yung Shin Pharm. Ind. Co. Ltd.	Formulation pharmaceutique stable de cabazitaxel
CN103664836B (zh) *	2012-09-20	2016-04-20	齐鲁制药有限公司	7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
WO2014055493A1 (fr)	2012-10-02	2014-04-10	Cerulean Pharma Inc.	Procédés et systèmes s'appliquant à la précipitation de polymères et à la génération de particules
CN103804323A (zh) *	2012-11-14	2014-05-21	上海希迈医药科技有限公司	一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) *	2012-12-12	2014-12-10	江苏奥赛康药业股份有限公司	卡巴他赛多晶型形式及其制备方法
EP2743264A1 (fr)	2012-12-13	2014-06-18	INDENA S.p.A.	Nouvelle forme cristalline de cabazitaxel, procédé de préparation et ses compositions pharmaceutiques
CN103910696B (zh) *	2012-12-30	2016-01-20	上海医药工业研究院	卡巴他赛异丙醚合物及其结晶
CN103910698B (zh) *	2012-12-30	2016-01-20	上海医药工业研究院	卡巴他赛丙酮合物及其结晶
EP2777691A1 (fr)	2013-03-14	2014-09-17	Pharmachemie B.V.	Taxoïde - purification des excipients liquides
EP2815749A1 (fr)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
WO2015000165A1 (fr) *	2013-07-04	2015-01-08	北京新天宇科技开发有限公司	Produit de transformation stable du mono-acétonate de dimethoxy docetaxel et ses formes cristallines, et leurs procédés de préparation
CN104277014A (zh) *	2013-07-04	2015-01-14	北京新天宇科技开发有限公司	二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865674A1 (fr)	2013-10-23	2015-04-29	INDENA S.p.A.	Formes dissoutes cristallines de Cabazitaxel
EP2865675A1 (fr) *	2013-10-23	2015-04-29	INDENA S.p.A.	Forme cristalline anhydre de Cabazitaxel, procédé de préparation et ses compositions pharmaceutiques
CN103601704B (zh) *	2013-11-22	2015-05-06	石家庄智恒医药科技有限公司	无定形卡巴他赛的制备
ES2904505T3 (es)	2015-01-12	2022-04-05	Emcure Pharmaceuticals Ltd	Formulación líquida de cabazitaxel
EP3258931B1 (fr) *	2015-02-17	2020-08-12	Erasmus University Medical Center Rotterdam	Utilisation de cabazitaxel pour le traitement du cancer de la prostate
EP3093014A1 (fr)	2015-05-13	2016-11-16	Aventis Pharma S.A.	Cabazitaxel et son utilisation pour le traitement du cancer
US10188626B2 (en)	2015-11-03	2019-01-29	Cipla Limited	Stabilized cabazitaxel formulations
CN110312721A (zh)	2016-11-29	2019-10-08	显莎制药公司	墨蝶呤的多晶型物
KR102561697B1 (ko)	2016-11-29	2023-07-28	피티씨 테라퓨틱스 엠피, 인크.	세피아프테린의 다형체 및 그의 염
JP2020532535A (ja)	2017-09-01	2020-11-12	ピーティーシーセラピューティクスエムピー，インコーポレイテッド	セピアプテリンを含む医薬組成物及びその使用
US12257252B2 (en)	2018-05-30	2025-03-25	Ptc Therapeutics Mp, Inc.	Compositions and methods for increasing tetrahydrobiopterin plasma exposure
DK3801536T3 (da)	2018-05-30	2024-08-19	Ptc Therapeutics Mp Inc	Indgivelse af sepiapterin uden mad til anvendelse i en fremgangsmåde til at øge sepiapterinplasmaeksponering
WO2020249507A1 (fr)	2019-06-11	2020-12-17	Indena S.P.A.	Forme cristalline anhydre du cabazitaxel, procédé pour sa préparation et compositions pharmaceutiques la contenant
EP3797834A1 (fr)	2019-09-25	2021-03-31	Sanofi Mature IP	Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène
EP3808345A1 (fr)	2019-10-15	2021-04-21	Sanofi Mature IP	Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5766635A (en) *	1991-06-28	1998-06-16	Rhone-Poulenc Rorer S.A.	Process for preparing nanoparticles
FR2722191B1 (fr) *	1994-07-08	1996-08-23	Rhone Poulenc Rorer Sa	Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
DE4425978C1 (de) *	1994-07-22	1995-11-23	Karlsruhe Forschzent	Verfahren zur Herstellung keramischer Mikrostrukturen
MA23823A1 (fr) *	1995-03-27	1996-10-01	Aventis Pharma Sa	Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) *	1996-03-06	1998-04-03	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr)	1997-11-18	1999-12-17	Rhone Poulenc Rorer Sa	Procede de preparation de derives de la classe des taxoides
EP0982027A1 (fr) *	1998-08-17	2000-03-01	Aventis Pharma S.A.	Dérivés taxoides pour traiter les proliférations cellulaires anormales du cerveau
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) *	1998-12-30	2000-10-24	Phytogen Life Sciences, Incorporated	Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) *	1999-01-07	1999-10-19	508037 (Nb) Inc.	Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
PT1178979E (pt) *	1999-05-17	2004-04-30	Bristol Myers Squibb Co	Novas condicoes de reaccao para a clivagem de eteres de sililo na preparacao de paclitaxel (taxol(r)) e analogos de paclitaxel
KR100886805B1 (ko) *	2001-11-29	2009-03-05	다이이찌 세이야꾸 가부시기가이샤	탁산 유도체 결정 및 그 제조방법

2003
- 2003-09-19 FR FR0311016A patent/FR2859996B1/fr not_active Expired - Lifetime
2004
- 2004-08-19 PE PE2004000799A patent/PE20050870A1/es not_active Application Discontinuation
- 2004-09-16 EP EP04787385A patent/EP1667986B1/fr not_active Expired - Lifetime
- 2004-09-16 PA PA20048612401A patent/PA8612401A1/es unknown
- 2004-09-16 MX MXPA06002639A patent/MXPA06002639A/es active IP Right Grant
- 2004-09-16 RS YUP-2006/0189A patent/RS20060189A/sr unknown
- 2004-09-16 BR BRPI0414492A patent/BRPI0414492A8/pt not_active Application Discontinuation
- 2004-09-16 CA CA002539309A patent/CA2539309A1/fr not_active Abandoned
- 2004-09-16 AU AU2004274212A patent/AU2004274212B2/en active Active
- 2004-09-16 JP JP2006526663A patent/JP5010279B2/ja not_active Expired - Lifetime
- 2004-09-16 CN CNB200480026128XA patent/CN100429207C/zh not_active Expired - Lifetime
- 2004-09-16 WO PCT/FR2004/002344 patent/WO2005028462A1/fr not_active Ceased
- 2004-09-16 ME MEP-2008-117A patent/ME00054B/me unknown
- 2004-09-16 AR ARP040103329A patent/AR045667A1/es not_active Application Discontinuation
- 2004-09-16 HR HRP20130322TT patent/HRP20130322T1/hr unknown
- 2004-09-16 DK DK04787385.6T patent/DK1667986T3/da active
- 2004-09-16 PT PT4787385T patent/PT1667986E/pt unknown
- 2004-09-16 RS RS20060189A patent/RS54614B1/sr unknown
- 2004-09-16 UA UAA200604360A patent/UA87115C2/ru unknown
- 2004-09-16 SI SI200432016T patent/SI1667986T1/sl unknown
- 2004-09-16 RU RU2006113122/04A patent/RU2342373C2/ru active Protection Beyond IP Right Term
- 2004-09-16 PL PL04787385T patent/PL1667986T3/pl unknown
- 2004-09-16 ME MEP-117/08A patent/MEP11708A/xx unknown
- 2004-09-16 KR KR1020067005396A patent/KR101123588B1/ko not_active Expired - Lifetime
- 2004-09-16 ES ES04787385T patent/ES2403149T4/es not_active Expired - Lifetime
- 2004-09-16 NZ NZ545835A patent/NZ545835A/en not_active IP Right Cessation
- 2004-09-17 US US10/944,254 patent/US7241907B2/en not_active Expired - Lifetime
- 2004-09-17 TW TW093128097A patent/TWI382022B/zh not_active IP Right Cessation
- 2004-09-17 MY MYPI20043787A patent/MY136668A/en unknown
2006
- 2006-03-09 IL IL174240A patent/IL174240A/en active IP Right Grant
- 2006-03-15 CR CR8292A patent/CR8292A/es unknown
- 2006-03-17 ZA ZA200602255A patent/ZA200602255B/en unknown
- 2006-03-17 TN TNP2006000086A patent/TNSN06086A1/en unknown
- 2006-03-17 MA MA28881A patent/MA28045A1/fr unknown
- 2006-04-19 NO NO20061714A patent/NO335997B1/no active Protection Beyond IP Right Term
2013
- 2013-03-20 LU LU92172C patent/LU92172I2/fr unknown
- 2013-04-16 CY CY20131100313T patent/CY1114575T1/el unknown
- 2013-05-13 CY CY2013016C patent/CY2013016I1/el unknown
- 2013-06-07 HU HUS1300025C patent/HUS1300025I1/hu unknown
- 2013-06-13 BE BE2013C036C patent/BE2013C036I2/fr unknown
- 2013-07-04 FR FR13C0037C patent/FR13C0037I2/fr active Active
2015
- 2015-04-22 NO NO2015013C patent/NO2015013I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
BRPI0414492A (pt)	2006-11-14
JP5010279B2 (ja)	2012-08-29
AU2004274212B2 (en)	2010-03-04
BRPI0414492A8 (pt)	2019-01-15
UA87115C2 (ru)	2009-06-25
US7241907B2 (en)	2007-07-10
CY2013016I2 (el)	2018-01-10
PA8612401A1 (es)	2005-08-04
ME00054B (me)	2011-02-10
NO20061714L (no)	2006-04-19
MEP11708A (en)	2010-06-10
EP1667986A1 (fr)	2006-06-14
NZ545835A (en)	2009-10-30
CN1849311A (zh)	2006-10-18
KR101123588B1 (ko)	2012-03-22
RS20060189A (sr)	2008-06-05
LU92172I9 (fr)	2019-01-03
MXPA06002639A (es)	2006-06-05
ES2403149T3 (es)	2013-05-14
FR2859996B1 (fr)	2006-02-03
KR20060072147A (ko)	2006-06-27
CN100429207C (zh)	2008-10-29
HUS1300025I1 (hu)	2016-08-29
PE20050870A1 (es)	2005-11-21
PL1667986T3 (pl)	2013-06-28
TWI382022B (zh)	2013-01-11
DK1667986T3 (da)	2013-05-06
HRP20130322T1 (en)	2013-07-31
TW200524891A (en)	2005-08-01
RU2342373C2 (ru)	2008-12-27
AR045667A1 (es)	2005-11-02
CA2539309A1 (fr)	2005-03-31
PT1667986E (pt)	2013-04-24
CR8292A (es)	2008-10-15
ZA200602255B (en)	2007-07-25
FR2859996A1 (fr)	2005-03-25
BE2013C036I2 (fr)	2023-12-14
HK1093340A1 (zh)	2007-03-02
FR13C0037I1 (fr)	2013-09-08
NO2015013I2 (no)	2015-04-22
MY136668A (en)	2008-11-28
AU2004274212A1 (en)	2005-03-31
IL174240A (en)	2010-12-30
TNSN06086A1 (en)	2007-10-03
ES2403149T4 (es)	2013-06-24
RS54614B1 (sr)	2016-08-31
US20050065138A1 (en)	2005-03-24
EP1667986B1 (fr)	2013-01-16
NO2015013I1 (no)	2015-05-04
LU92172I2 (fr)	2013-05-21
IL174240A0 (en)	2006-08-01
RU2006113122A (ru)	2006-08-27
MA28045A1 (fr)	2006-07-03
CY1114575T1 (el)	2016-10-05
CY2013016I1 (el)	2018-01-10
JP2007505866A (ja)	2007-03-15
NO335997B1 (no)	2015-04-20
SI1667986T1 (sl)	2013-05-31
WO2005028462A1 (fr)	2005-03-31

Publication	Publication Date	Title
FR13C0037I2 (fr)	2015-11-20	Solvat acetonique du dimethoxy docetaxel et son procede de preparation
EP1605742A4 (fr)	2010-03-03	Structure de blindage magnetique ouverte et son ossature magnetique
LUC00127I1 (fr)	2019-09-19	Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
EP1663259A4 (fr)	2009-07-29	Compositions et methodes de traitement du cancer
FR2854158B1 (fr)	2006-11-17	Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2864080B1 (fr)	2006-02-03	Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
NO20061691L (no)	2006-06-15	Deigformende apparat
FR2854633B1 (fr)	2005-06-24	Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2868780B1 (fr)	2008-10-17	Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
FR2872813B1 (fr)	2007-01-19	Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
EP1584084A4 (fr)	2009-12-16	Structure de pixel et procede de fabrication associe
EP1793198A4 (fr)	2013-02-20	Procede d'examen d'ovd et instrument d'examen d'ovd
FR2843964B1 (fr)	2004-10-01	Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
FR2856684B1 (fr)	2008-04-11	Derives de diphenylpyridine, leur preparation et leur application en therapeutique
FR2882054B1 (fr)	2007-04-13	Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2866888B1 (fr)	2006-05-05	Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
MA27233A1 (fr)	2005-02-01	Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique
FR2891828B1 (fr)	2007-12-21	Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
FR2837824B1 (fr)	2006-03-03	Nouveaux derives de la podophyllotoxine, leur preparation et leur application en therapeutique
NO20053874D0 (no)	2005-08-18	Formulering og metoder for behandling av thrombocytemi
EP1406496A4 (fr)	2004-12-15	Methode et composition permettant de stimuler le desir sexuel
EP1626711A4 (fr)	2010-10-06	Compositions et methodes de traitement anticancereux
EP1649758A4 (fr)	2007-04-25	Capsule masticable et procede de fabrication
FR2860792B1 (fr)	2006-02-24	Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
FR2866245B1 (fr)	2006-03-31	Nouveaux agents epaississants et leur procede de preparation